Why Eton Pharmaceuticals Is Top of the Class Today

Why Eton Pharmaceuticals Is Top of the Class Today

Rich Smith, The Motley Fool

Fri, August 14, 2026 at 9:58 PM GMT+3 3 min read

• ETON +44.26%
• NVDA -0.06%

Eton Pharmaceuticals (NASDAQ: ETON) stock soared 41.9% through 2:15 p.m. ET Friday after beating analyst forecasts for Q2 with a stick.

Heading into the report, Wall Street had Eton pegged for a $0.15 per share profit on just $26.9 million in sales. Instead, the developer of drugs for rare diseases announced a profit of $0.43 per share -- and $37.6 million in sales.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Eton Q2 earnings

Eton all but doubled its sales year over year -- 99% growth -- and flipped from a $0.10 per share GAAP loss to a $0.35 per share profit in Q2. (The $0.42 figure was a non-GAAP number.) Free cash flow for the quarter totaled $7.3 million, bringing the company's year-to-date FCF to $14.6 million.

That said, if you subtract out the cost of product licensing rights -- $15 million -- free cash flow would have been negative. This isn't a constant expense for Eton, appearing some years but absent or minimal in others. Still, Eton noted that it has just licensed the rights to infantile hemangioma drug candidate ASN-001 from Auson Pharmaceuticals, so there's an argument to be made that it may become an ongoing expense, and should be subtracted when calculating free cash flow.

What's next for Eton stock

Positive free cash flow or no, investors seem fine with the results -- and with guidance as well.

Eton raised its guidance through the end of this year, predicting revenue will exceed $145 million, well above Wall Street's expected $121 million. The company raised its guidance for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) as well (despite the added expense from ASN-001).

Valued at 94.5 times earnings, Eton's not a cheap stock. But at its current growth rate, it just might be worth the price.

Should you buy stock in Eton Pharmaceuticals right now?

Before you buy stock in Eton Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eton Pharmaceuticals wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $421,943!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,382,819!*

That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of August 14, 2026.

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eton Pharmaceuticals. The Motley Fool has a disclosure policy.

Why Eton Pharmaceuticals Is Top of the Class Today was originally published by The Motley Fool